Four hundred people recovered in Pisa thanks to the ancient monoclonals
The head of Infectious Diseases of Cisanello: “Right now the only winning therapy against the coronavirus”
PISA. «Monoclonal offers represent the only winning therapy against the coronavirus right now. There are no others. Pisa represents an Italian model for the connection between hospital and territory and in the ability to administer high numbers of monoclonal capacities. 400 people treated and healed in these months ». These are the words spoken by Marco Falcone, infectious disease specialist of the Pisan university-hospital company, interim substitute for Francesco Menichetti, recently retired head of Infectious Diseases. Marco Falcone intervened via video link at the Fimmg headquarters in Pisa to take stock of the situation of Covid in Pisa and what are the current medical treatments capable of neutralizing the virus.
The experience of Pisa – continued Falcone – proved to be extremely positive and almost unique, thanks to a collaboration and a territorial network developed with family doctors ». Pisa, Arezzo and Florence were in fact the three offices that, in Tuscany, used the Aifa monoclonals more exclusively. «The only cure in the early therapy of Covid – specified Falcone -: a stock of preformed products that the sick person receives and whose effects in terms of time are practically immediate. On this in Pisa we have created one of the most important experiences in Italy, with an absolutely effective model ». Falcone then illustrated the data relating to the administrations and the two protocols in force.
«We started on 9 March 2021 with the first monoclonals to which others have been added over time, from AstraZeneca to Eli Lilly, Roche up to Tls. We have practically treated over 400 patients and found a very high efficacy in preventing death and hospitalization, if we think that less than 5% of these people – said Falcone – have been hospitalized or died. ” the administration of monoclonals within 3 days of confirmed Covid positivity. “And only in the Pisan area – explained Luca Puccetti, Fimmg secretary of Pisa – the administration of monoclonal bacteria represents 20% of the total of our region”